Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsConference on FY2025.12 Q3 Financial Results
FY2025 Q3 Overview
Dr. Osamu Okuda,
President & CEO
Overview of Development Pipeline
Tsukasa Kusano,
Executive Vice President, Head of Project & Lifecycle Management Unit
FY2025 Q3 Consolidated Financial Overview (Core)
Iwaaki Taniguchi,
Director, Executive Vice President & CFO
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2024(Integrated Report)
Past Annual Report
What's New
-
Script (including Q&A) for Conference on FY2025.12 Q3 Financial Results
-
The dates of the Financial Results for 2025 FY, 2026 Q1, Q2, and Q3 have been updated.
-
Conference on FY 2025.12 Q3 Financial Results
-
Financial Results for Third Quarter of Fiscal Year 2025 (Jan-Sep 2025)
-
Events & Presentations has been updated with the Date of Sustainability Meeting
-
Chugai Announces 2025 3rd Quarter Results
-
Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary
-
F. Hoffmann-La Roche Announces Third Quarter Sales 2025
-
Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer
-
Roche’s Announcement Regarding Tecentriq (Presentation of Latest Data as an Adjuvant Treatment in Muscle-Invasive Bladder Cancer at ESMO)
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
